Glioblastoma Multiforme Treatment (GBM) Market Report

Global and Region Glioblastoma Multiforme Treatment (GBM) Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：231
  • REPORT CODE：GMM1016863
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Glioblastoma is a fast-growing, aggressive type of central nervous system tumor that forms on the supportive tissue of the brain.

    Global glioblastoma multiforme treatment market is expected to witness significant growth over the forecast period owing to the rising incidence of oncology diseases and rising geriatric population base.

    The report details the trend, potential and market size of Glioblastoma Multiforme Treatment (GBM) market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Glioblastoma Multiforme Treatment (GBM)market, defines the market attractiveness level of Glioblastoma Multiforme Treatment (GBM) market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Glioblastoma Multiforme Treatment (GBM) industry, describes the types of Glioblastoma Multiforme Treatment (GBM) market, the applications of major players and the market size, and deeply analyzes the current situation of the global Glioblastoma Multiforme Treatment (GBM) market and the development prospects and opportunities of Glioblastoma Multiforme Treatment (GBM) industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Glioblastoma Multiforme Treatment (GBM) market in Chapter 13.

    By Player:

    • Teva Pharmaceutical Industries Ltd

    • Pfizer Inc

    • Karyopharm Therapeutics, Inc

    • Merck & Co, Inc

    • Sumitomo Dainippon Pharma Oncology, Inc

    • F Hoffmann-La Roche Ltd

    • Sun Pharmaceutical Industries Ltd

    • Amneal Pharmaceuticals

    • Arbor Pharmaceuticals, LLC

    • Amgen, Inc

    By Type:

    • Temozolomide

    • Bevacizumab

    • Lomustine

    • Carmustine Wafers

    • Others

    By End-User:

    • Hospitals

    • Clinics

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Glioblastoma Multiforme Treatment (GBM) Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Glioblastoma Multiforme Treatment (GBM) Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Glioblastoma Multiforme Treatment (GBM) Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Glioblastoma Multiforme Treatment (GBM) Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Glioblastoma Multiforme Treatment (GBM) Market Analysis and Outlook to 2022

    • 7.1 Global Glioblastoma Multiforme Treatment (GBM) Consumption (2017-2022)

    • 7.2 United States Glioblastoma Multiforme Treatment (GBM) Consumption (2017-2022)

    • 7.3 Europe Glioblastoma Multiforme Treatment (GBM) Consumption (2017-2022)

    • 7.4 China Glioblastoma Multiforme Treatment (GBM) Consumption (2017-2022)

    • 7.5 Japan Glioblastoma Multiforme Treatment (GBM) Consumption (2017-2022)

    • 7.6 India Glioblastoma Multiforme Treatment (GBM) Consumption (2017-2022)

    • 7.7 South Korea Glioblastoma Multiforme Treatment (GBM) Consumption (2017-2022)

    8 Region and Country-wise Glioblastoma Multiforme Treatment (GBM) Market Analysis and Outlook to 2028

    • 8.1 Global Glioblastoma Multiforme Treatment (GBM) Consumption Forecast (2022-2028)

    • 8.2 United States Glioblastoma Multiforme Treatment (GBM) Consumption Forecast (2022-2028)

    • 8.3 Europe Glioblastoma Multiforme Treatment (GBM) Consumption Forecast (2022-2028)

    • 8.4 China Glioblastoma Multiforme Treatment (GBM) Consumption Forecast (2022-2028)

    • 8.5 Japan Glioblastoma Multiforme Treatment (GBM) Consumption Forecast (2022-2028)

    • 8.6 India Glioblastoma Multiforme Treatment (GBM) Consumption Forecast (2022-2028)

    • 8.7 South Korea Glioblastoma Multiforme Treatment (GBM) Consumption Forecast (2022-2028)

    9 Global Glioblastoma Multiforme Treatment (GBM) Market Outlook by Types and Applications to 2022

    • 9.1 Global Glioblastoma Multiforme Treatment (GBM) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Temozolomide Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Bevacizumab Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Lomustine Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Carmustine Wafers Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Glioblastoma Multiforme Treatment (GBM) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

    10 Global Glioblastoma Multiforme Treatment (GBM) Market Outlook by Types and Applications to 2028

    • 10.1 Global Glioblastoma Multiforme Treatment (GBM) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Temozolomide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Bevacizumab Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Lomustine Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Carmustine Wafers Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Glioblastoma Multiforme Treatment (GBM) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    11 Global Glioblastoma Multiforme Treatment (GBM) Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Glioblastoma Multiforme Treatment (GBM) Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Glioblastoma Multiforme Treatment (GBM) Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Glioblastoma Multiforme Treatment (GBM) Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Glioblastoma Multiforme Treatment (GBM) Market Competitive Analysis

    • 14.1 Teva Pharmaceutical Industries Ltd

      • 14.1.1 Teva Pharmaceutical Industries Ltd Company Details

      • 14.1.2 Teva Pharmaceutical Industries Ltd Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Teva Pharmaceutical Industries Ltd Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.2 Pfizer Inc

      • 14.2.1 Pfizer Inc Company Details

      • 14.2.2 Pfizer Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Pfizer Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.3 Karyopharm Therapeutics, Inc

      • 14.3.1 Karyopharm Therapeutics, Inc Company Details

      • 14.3.2 Karyopharm Therapeutics, Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Karyopharm Therapeutics, Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.4 Merck & Co, Inc

      • 14.4.1 Merck & Co, Inc Company Details

      • 14.4.2 Merck & Co, Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Merck & Co, Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.5 Sumitomo Dainippon Pharma Oncology, Inc

      • 14.5.1 Sumitomo Dainippon Pharma Oncology, Inc Company Details

      • 14.5.2 Sumitomo Dainippon Pharma Oncology, Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Sumitomo Dainippon Pharma Oncology, Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.6 F Hoffmann-La Roche Ltd

      • 14.6.1 F Hoffmann-La Roche Ltd Company Details

      • 14.6.2 F Hoffmann-La Roche Ltd Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 F Hoffmann-La Roche Ltd Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.7 Sun Pharmaceutical Industries Ltd

      • 14.7.1 Sun Pharmaceutical Industries Ltd Company Details

      • 14.7.2 Sun Pharmaceutical Industries Ltd Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Sun Pharmaceutical Industries Ltd Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.8 Amneal Pharmaceuticals

      • 14.8.1 Amneal Pharmaceuticals Company Details

      • 14.8.2 Amneal Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Amneal Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.9 Arbor Pharmaceuticals, LLC

      • 14.9.1 Arbor Pharmaceuticals, LLC Company Details

      • 14.9.2 Arbor Pharmaceuticals, LLC Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Arbor Pharmaceuticals, LLC Glioblastoma Multiforme Treatment (GBM) Product and Service

    • 14.10 Amgen, Inc

      • 14.10.1 Amgen, Inc Company Details

      • 14.10.2 Amgen, Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Amgen, Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Glioblastoma Multiforme Treatment (GBM)

    • Figure Glioblastoma Multiforme Treatment (GBM) Picture

    • Table Global Glioblastoma Multiforme Treatment (GBM) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Glioblastoma Multiforme Treatment (GBM) Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Glioblastoma Multiforme Treatment (GBM) Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Glioblastoma Multiforme Treatment (GBM) Consumption by Country (2017-2022)

    • Figure United States Glioblastoma Multiforme Treatment (GBM) Consumption and Growth Rate (2017-2022)

    • Table Europe Glioblastoma Multiforme Treatment (GBM) Consumption and Growth Rate (2017-2022)

    • Figure China Glioblastoma Multiforme Treatment (GBM) Consumption and Growth Rate (2017-2022)

    • Figure Japan Glioblastoma Multiforme Treatment (GBM) Consumption and Growth Rate (2017-2022)

    • Figure India Glioblastoma Multiforme Treatment (GBM) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Glioblastoma Multiforme Treatment (GBM) Consumption and Growth Rate (2017-2022)

    • Figure Global Glioblastoma Multiforme Treatment (GBM) Consumption Forecast by Country (2022-2028)

    • Figure United States Glioblastoma Multiforme Treatment (GBM) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Glioblastoma Multiforme Treatment (GBM) Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Glioblastoma Multiforme Treatment (GBM) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Glioblastoma Multiforme Treatment (GBM) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Glioblastoma Multiforme Treatment (GBM) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Glioblastoma Multiforme Treatment (GBM) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Temozolomide Consumption and Growth Rate (2017-2022)

    • Figure Global Bevacizumab Consumption and Growth Rate (2017-2022)

    • Figure Global Lomustine Consumption and Growth Rate (2017-2022)

    • Figure Global Carmustine Wafers Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Temozolomide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Bevacizumab Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lomustine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Carmustine Wafers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Glioblastoma Multiforme Treatment (GBM) Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Glioblastoma Multiforme Treatment (GBM) Export by Region (Top 5 Countries) (2017-2028)

    • Table Teva Pharmaceutical Industries Ltd (Foundation Year, Company Profile and etc.)

    • Table Teva Pharmaceutical Industries Ltd Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceutical Industries Ltd Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table Pfizer Inc (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table Karyopharm Therapeutics, Inc (Foundation Year, Company Profile and etc.)

    • Table Karyopharm Therapeutics, Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Karyopharm Therapeutics, Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table Merck & Co, Inc (Foundation Year, Company Profile and etc.)

    • Table Merck & Co, Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co, Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table Sumitomo Dainippon Pharma Oncology, Inc (Foundation Year, Company Profile and etc.)

    • Table Sumitomo Dainippon Pharma Oncology, Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sumitomo Dainippon Pharma Oncology, Inc Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann-La Roche Ltd Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table Sun Pharmaceutical Industries Ltd (Foundation Year, Company Profile and etc.)

    • Table Sun Pharmaceutical Industries Ltd Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sun Pharmaceutical Industries Ltd Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table Amneal Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Amneal Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amneal Pharmaceuticals Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table Arbor Pharmaceuticals, LLC (Foundation Year, Company Profile and etc.)

    • Table Arbor Pharmaceuticals, LLC Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arbor Pharmaceuticals, LLC Glioblastoma Multiforme Treatment (GBM) Product and Service

    • Table Amgen, Inc (Foundation Year, Company Profile and etc.)

    • Table Amgen, Inc Glioblastoma Multiforme Treatment (GBM) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen, Inc Glioblastoma Multiforme Treatment (GBM) Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US